Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Fluciclovine 18F (Primary) ; TLX591 companion diagnostic Telix Pharmaceuticals (Primary)
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer
- Focus Diagnostic use
- 11 May 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2022 According to a Telix Pharmaceuticals media release, data from this study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
- 17 Aug 2021 According to a Telix Pharmaceuticals media release, first patient has been dosed in the study.